Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. (CompareAcute)
Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease
Sponsor: Abbott Medical Devices
Listed as NCT01399736, this NA trial focuses on Multivessel Coronary Artery Disease and Myocardial Infarction and remains completed. Sponsored by Abbott Medical Devices, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
▶ Show 6 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Completed NA
Phase: PHASE4 → NA
-
Feb 2019 — Aug 2020 [monthly]
Completed PHASE4
-
Dec 2018 — Feb 2019 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE4
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- Maasstad Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arnhem, Netherlands , Bad Krozingen, Germany , Bad Segeberg, Germany , Bremen, Germany , Brno, Czechia , Budapest, Hungary , Gothenburg, Sweden , Groningen, Netherlands , Heerlen, Netherlands , Hradec Králové, Czechia and 14 more locations